Summary of Study ST002116
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001341. The data can be accessed directly via it's Project DOI: 10.21228/M8CM41 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002116 |
| Study Title | Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt based drugs |
| Study Summary | Pt based drugs play a very important role in current cancer treatment; yet their cellular and mechanistic aspects are not fully understood. NMR metabolomics provides a powerful tool to investigate the metabolic perturbations induced by Pt drugs in cancer cells and decipher their meaning in relation to the presumed molecular mechanisms. We have carried out a systematic and comparative NMR metabolomics study to analyze the responses of A2780 human ovarian cancer cells to the main clinically established Pt drugs, i.e. cisplatin, carboplatin and oxaliplatin, with a particular attention for the oxaliplatin/cisplatin comparison in view of recently described mechanistic differences. Notably, NMR analysis revealed some moderate and consistent changes in the metabolomic profiles of A2780 cells treated with the 3 Pt drugs with respect to controls but only very small differences among them. Beyond the expected alterations at the level of the nucleic acids the observed changes highlight in all cases induction of a significant ER stress. Owing to the clinical relevance of platinum resistance the behavior of a cisplatin resistant A2780 cancer cell line upon cisplatin treatment was also evaluated. |
| Institute | University of Florence |
| Department | Department of Chemistry |
| Laboratory | Metabolomics |
| Last Name | Ghini |
| First Name | Veronica |
| Address | via Luigi Sacconi 6 |
| turano@cerm.unifi.it | |
| Phone | +390554574266 |
| Submit Date | 2022-03-22 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | fid |
| Analysis Type Detail | NMR |
| Release Date | 2022-10-03 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001341 |
| Project DOI: | doi: 10.21228/M8CM41 |
| Project Title: | Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt based drugs |
| Project Summary: | Pt based drugs play a very important role in current cancer treatment; yet their cellular and mechanistic aspects are not fully understood. NMR metabolomics provides a powerful tool to investigate the metabolic perturbations induced by Pt drugs in cancer cells and decipher their meaning in relation to the presumed molecular mechanisms. We have carried out a systematic and comparative NMR metabolomics study to analyze the responses of A2780 human ovarian cancer cells to the main clinically established Pt drugs, i.e. cisplatin, carboplatin and oxaliplatin, with a particular attention for the oxaliplatin/cisplatin comparison in view of recently described mechanistic differences. Notably, NMR analysis revealed some moderate and consistent changes in the metabolomic profiles of A2780 cells treated with the 3 Pt drugs with respect to controls but only very small differences among them. Beyond the expected alterations at the level of the nucleic acids the observed changes highlight in all cases induction of a significant ER stress. Owing to the clinical relevance of platinum resistance the behavior of a cisplatin resistant A2780 cancer cell line upon cisplatin treatment was also evaluated. |
| Institute: | University of Florence |
| Department: | Department of Chemistry |
| Laboratory: | Metabolomics |
| Last Name: | Ghini |
| First Name: | Veronica |
| Address: | via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy |
| Email: | ghini@cerm.unifi.it |
| Phone: | +39 3922800462 |
Subject:
| Subject ID: | SU002201 |
| Subject Type: | Cultured cells |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Cell Strain Details: | A2780 ovarian cancer cells |
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | sample_type |
|---|---|---|
| SA202984 | Cell-CARBO-24h-4 | lysate | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA202985 | Cell-Carbo-24h-2 | lysate | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA202986 | Cell-Carbo-24h-1 | lysate | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA202987 | Cell-Carbo-48h-4 | lysate | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA202988 | Cell-Carbo-48h-3 | lysate | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA202989 | Cell-Carbo-48h-1 | lysate | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA202990 | Cell-CIS-24h-4 | lysate | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA202991 | Cell-Cis-24h-2 | lysate | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA202992 | Cell-Cis-24h-1 | lysate | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA202993 | Cell-Cis-48h-4 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA202994 | Cell-Cis-48h-1 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA202995 | Cell-Cis-48h-3 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA202996 | Cell-Cis-R-48h-3-2810 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA202997 | Cell-Cis-R-48h-2-2110 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA202998 | Cell-Cis-R-48h-1-1411 | lysate | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA202999 | Cell-Ctr-24h-1 | lysate | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203000 | Cell-Ctr-24h-4 | lysate | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203001 | Cell-Ctr-24h-2 | lysate | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203002 | Cell-Ctr-48h-1 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203003 | Cell-Ctr-48h-4 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203004 | Cell-Ctr-48h-3 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203005 | Cell-Cont-R-48h-1-1411 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203006 | Cell-Cont-R-48h-3-2810 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203007 | Cell-Cont-R-48h-2-2110 | lysate | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203008 | Cell-Oxa-24h-1 | lysate | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203009 | Cell-OXA-24h-4 | lysate | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203010 | Cell-Oxa-24h-2 | lysate | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203011 | Cell-Oxa-48h-1 | lysate | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| SA203012 | Cell-Oxa-48h-4 | lysate | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| SA203013 | Cell-Oxa-48h-3 | lysate | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| SA203014 | SN-Carbo-24h-4 | medium | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA203015 | SN-CARBO-24h-1 | medium | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA203016 | SN-CARBO-24h-2 | medium | treatment_type:carboplatin | treatment_time:24 | cell_line:A2780 |
| SA203017 | SN-CARBO-48h-1 | medium | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA203018 | SN-CARBO-48h-4 | medium | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA203019 | SN-CARBO-48h-3 | medium | treatment_type:carboplatin | treatment_time:48 | cell_line:A2780 |
| SA203020 | SN-Cis-24h-4 | medium | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA203021 | SN-CIS-24h-1 | medium | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA203022 | SN-CIS-24h-2 | medium | treatment_type:cisplatin | treatment_time:24 | cell_line:A2780 |
| SA203023 | SN-CIS-48h-4 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA203024 | SN-CIS-48h-3 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA203025 | SN-CIS-48h-1 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780 |
| SA203026 | SN-CIS-R-48h-3-2810 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA203027 | SN-CIS-R-48h-2-2110 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA203028 | SN-CIS-R-48h-1-1411 | medium | treatment_type:cisplatin | treatment_time:48 | cell_line:A2780cp |
| SA203029 | SN-CTR-24h-2 | medium | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203030 | SN-Ctr-24h-4 | medium | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203031 | SN-CTR-24h-1 | medium | treatment_type:control | treatment_time:24 | cell_line:A2780 |
| SA203032 | SN-CTR-48h-3 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203033 | SN-CTR-48h-4 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203034 | SN-CTR-48h-1 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780 |
| SA203035 | SN-Cont-R-48h-1-1411 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203036 | SN-Cont-R-48h-3-2810 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203037 | SN-Cont-R-48h-2-2110 | medium | treatment_type:control | treatment_time:48 | cell_line:A2780cp |
| SA203038 | SN-OXA-24h-1 | medium | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203039 | SN-Oxa-24h-4 | medium | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203040 | SN-OXA-24h-2 | medium | treatment_type:oxaliplatin | treatment_time:24 | cell_line:A2780 |
| SA203041 | SN-OXA-48h-1 | medium | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| SA203042 | SN-OXA-48h-4 | medium | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| SA203043 | SN-OXA-48h-3 | medium | treatment_type:oxaliplatin | treatment_time:48 | cell_line:A2780 |
| Showing results 1 to 60 of 60 |
Collection:
| Collection ID: | CO002194 |
| Collection Summary: | A2780 cells were purchase from Sigma-Aldrich and derived from the European Collection of Authenticated Cell Culture (human ovarian carcinoma; catalogue no.: 93112519; lot no.13J012, passage no.: P + 9). A2780cp cells were kindly provided by Dr Simona Bracini and were obtained via prolonged exposition to sub-lethal dose of cisplatin. Cells were maintained in RPMI1640 medium supplemented with 2 mM glutamine, 10% of FCS and antibiotics at 37 °C in a 5% CO2 atmosphere and sub-cultured twice weekly. Split 1:5 (3–6 × 10^4 cells per mL). |
| Sample Type: | Cultured cells |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR002213 |
| Treatment Summary: | For drug treatment, 2.7 *10^6 A2780 cells were seeded in p100 plate and after 24 hours were exposed to a concentration of the three Pt-drugs, i.e. CIS, OXA and CARBO equal to their 72 h-exposure IC50 value (2.5, 55 and 0.46 uM, respectively). The drug incubations were stopped at two different time points, 24 h and 48 h. The A2780cp cells were exposed to a concentration of cisplatin equal to their 72 h-exposure IC50 value (15 uM). The drug incubation was stopped after 48 h of treatment. |
| Treatment: | Cisplatin, carboplatin and oxaliplatin |
| Cell Media: | RPMI1640 |
Sample Preparation:
| Sampleprep ID: | SP002207 |
| Sampleprep Summary: | Frozen samples were thawed at room temperature and shaken before use. For cell lysates, 50 μl of 2H2O were added to 450 μl of each lysate sample. In the case of cell culture media, 300 μl of sodium phosphate buffer (70 mM Na2HPO4; 20% v/v 2H2O; 4.6 mM TMSP, pH 7.4) was added to 300 μl of each medium sample. The mixtures were homogenized by vortexing for 30 s and transferred into 5 mm NMR tubes (Bruker BioSpin srl) for analysis. |
Analysis:
| Analysis ID: | AN003464 |
| Laboratory Name: | Metabolomics |
| Analysis Type: | NMR |
| Results File: | ST002116_AN003464_Results.txt |
| Units: | ppm |
NMR:
| NMR ID: | NM000235 |
| Analysis ID: | AN003464 |
| Instrument Name: | Bruker Advance 600 MHZ |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D-1H |
| Spectrometer Frequency: | 600 MHz |
| NMR Tube Size: | 5,00 mm |
| Water Suppression: | water presaturation |
| Temperature: | 300 K for lysates and 31o for media |
